News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Access to medicines and treatment news

Show

From To
PrEP policies and guidelines
PrEP Pricing Is the Elephant in the Room at the CDC National HIV Prevention Conference

Pre-exposure prophylaxis (PrEP) was supposed to usher in an end to the HIV epidemic. Now, seven years after its approval, it's clear that the once-daily pill has failed to reach the very patients who need it most. For veteran HIV researcher Michael Saag, M.D., with the University of Alabama at Birmingham, the reason is simple: PrEP is too expensive.

Published
24 March 2019
From
The Body
Access to medicines and treatment
Little advice in place for patients in England if drug supplies dry up

The Department of Health and Social Care and NHS England have given little practical advice to patients in England about what they can do if they are left unable to get hold of their normal drugs.

Published
24 March 2019
From
The Guardian
Access to medicines and treatment
Interview With Charles Gore, Medicines Patent Pool Executive Director

Charles Gore took over the role of Executive Director at the Medicines Patent Pool in July 2018, just after its board decided to greatly expand its mandate into essential medicines. Nine months into his term, IP-Watch’s William New talked with him about his role and how the expansion is going.

Published
24 March 2019
From
Intellectual Property Watch
Treatment-experienced people
South Africa: Shortage of drug puts thousands of Aids patients at risk

Health authorities have confirmed the shortage of Darunavir, a third-line drug. Third-line drugs are used when patients have few drug options left to treat their condition.

Published
15 March 2019
From
Independent Online
Retention and linkage to care
India’s first LGBTQ clinic and HIV treatment centre inaugurated in Mumbai

Based out of the Humsafar Trust’s office jn Mumbai, the centre will give free counselling and provide Anti-Retroviral Therapy (ART) to the LGBTQ community. TAshok Row Kavi, founder chairperson of the Trust, said: “Until now we would get testing done for the community members at our centre. If tested positive for the disease, they would be asked to go to Sion Hospital, but there was a huge dropout (rate) there. Because of how the community is perceived outside, a lot of these people wouldn’t seek treatment."

Published
12 March 2019
From
Hindustan Times
Delivery of care
EACS takes steps towards a common, auditable European standard of care

The purpose of the European AIDS Clinical Society's (EACS) meeting in January in Bucharest, Romania was to devise consistent, auditable standards of care for HIV, co-infection and

Published
11 March 2019
By
Gus Cairns
Finance and funding
Big Pharma Gave Money To Patient Advocacy Groups Opposing Medicare Changes

Dozens of patient advocacy groups, like the Bonnie J. Addario Lung Cancer Foundation and the National Coalition for Cancer Survivorship, recently appeared in national advertisements objecting to a Trump administration proposal that could limit drugs covered by Medicare providers. But a Kaiser Health News analysis found that about half of the groups representing patients have received funding from the pharmaceutical industry.

Published
05 March 2019
From
Kaiser Health News
PrEP
Should the NIH Break HIV Prevention Drug Truvada's Patent?

Should a biotech giant holding a valuable patent be forced to give it up if doing so would serve the public good? That’s the mounting debate over Gilead Sciences’ hold on an HIV prevention treatment, which some say is too expensive and should be available to all.

Published
05 March 2019
From
Fortune
Retention and linkage to care
San Francisco Is Beating H.I.V. Why Can’t Houston?

We know how to fight the epidemic, but patients in the South still aren’t getting the treatment they need.

Published
04 March 2019
From
The New York Times
PrEP
Examining the Truvada #BreakThePatent Debate: Gilead Responds

A review of how patents affect access to Truvada, and Gilead's response on calls for march-in rights to be granted on patents in order to facilitate access.

Published
04 March 2019
From
IPWatchdog.com
← Prev1...23456...145Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.